Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1990;68(Suppl):26–32.

Active and passive immunization against Plasmodium yoelii sporozoites.

Y Charoenvit 1, M Sedegah 1, L F Yuan 1, M Gross 1, C Cole 1, R Bechara 1, M F Leef 1, F A Robey 1, G H Lowell 1, R L Beaudoin 1
PMCID: PMC2393042  PMID: 1709834

Abstract

Three subunit vaccines based on the major repeat, (QGPGAP)n, and flanking regions of the Plasmodium yoelii circumsporozoite protein were designed, produced, and tested. All were immunogenic, but none gave consistent protection against a 40-200 sporozoite challenge. To demonstrate that antibodies to P. yoelii CS protein could provide protection we established a passive transfer model. Passive transfer of NYS1, an IgG3 MAb against the P. yoelii CS protein, protected 100% of mice against challenge with 5000 P. yoelii sporozoites. Binding of NYS1 to sporozoites was inhibited by incubation with (QGPGAP)2, indicating that the epitope on sporozoites recognized by this MAb was included within this peptide. The levels of antibodies to (QGPGAP)2 by ELISA, and to sporozoites by IFAT and CS precipitation reaction were similar in sera from mice that received NYS1 in passive transfer and were protected against challenge with 5000 sporozoites, and from mice that had been immunized with subunit vaccines containing QGPGAP but were not protected against challenge with 40-200 sporozoites. To determine if antibody avidity, not the absolute concentration, could explain the striking differences in protection, we established a thiocyanate elution assay. The results suggest that NYS1, the protective MAb, has a lower avidity for (QGPGAP)2 and for sporozoites than do the vaccine-induced antibodies. The data clearly demonstrate that antibodies to the CS protein can protect against intense sporozoite infection. Improved understanding of the differences between protective MAbs and non-protective polyclonal antibodies will be important in the further development of malaria vaccines.

Full text

PDF
26

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballou W. R., Hoffman S. L., Sherwood J. A., Hollingdale M. R., Neva F. A., Hockmeyer W. T., Gordon D. M., Schneider I., Wirtz R. A., Young J. F. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1987 Jun 6;1(8545):1277–1281. doi: 10.1016/s0140-6736(87)90540-x. [DOI] [PubMed] [Google Scholar]
  2. Ballou W. R., Rothbard J., Wirtz R. A., Gordon D. M., Williams J. S., Gore R. W., Schneider I., Hollingdale M. R., Beaudoin R. L., Maloy W. L. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science. 1985 May 24;228(4702):996–999. doi: 10.1126/science.2988126. [DOI] [PubMed] [Google Scholar]
  3. Collins W. E., Nussenzweig R. S., Ballou W. R., Ruebush T. K., 2nd, Nardin E. H., Chulay J. D., Majarian W. R., Young J. F., Wasserman G. F., Bathurst I. Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax. Am J Trop Med Hyg. 1989 May;40(5):455–464. doi: 10.4269/ajtmh.1989.40.455. [DOI] [PubMed] [Google Scholar]
  4. Hoffman S. L., Berzofsky J. A., Isenbarger D., Zeltser E., Majarian W. R., Gross M., Ballou W. R. Immune response gene regulation of immunity to Plasmodium berghei sporozoites and circumsporozoite protein vaccines. Overcoming genetic restriction with whole organism and subunit vaccines. J Immunol. 1989 May 15;142(10):3581–3584. [PubMed] [Google Scholar]
  5. Hoffman S. L., Wistar R., Jr, Ballou W. R., Hollingdale M. R., Wirtz R. A., Schneider I., Marwoto H. A., Hockmeyer W. T. Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N Engl J Med. 1986 Sep 4;315(10):601–606. doi: 10.1056/NEJM198609043151001. [DOI] [PubMed] [Google Scholar]
  6. Lal A. A., de la Cruz V. F., Welsh J. A., Charoenvit Y., Maloy W. L., McCutchan T. F. Structure of the gene encoding the circumsporozoite protein of Plasmodium yoelii. A rodent model for examining antimalarial sporozoite vaccines. J Biol Chem. 1987 Mar 5;262(7):2937–2940. [PubMed] [Google Scholar]
  7. Lowell G. H., Ballou W. R., Smith L. F., Wirtz R. A., Zollinger W. D., Hockmeyer W. T. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science. 1988 May 6;240(4853):800–802. doi: 10.1126/science.2452484. [DOI] [PubMed] [Google Scholar]
  8. McCutchan T. F., Lal A. A., de la Cruz V. F., Miller L. H., Maloy W. L., Charoenvit Y., Beaudoin R. L., Guerry P., Wistar R., Jr, Hoffman S. L. Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax. Science. 1985 Dec 20;230(4732):1381–1383. doi: 10.1126/science.2416057. [DOI] [PubMed] [Google Scholar]
  9. Pacheco N. D., Strome C. P., Mitchell F., Bawden M. P., Beaudoin R. L. Rapid, large-scale isolation of Plasmodium berghei sporozoites from infected mosquitoes. J Parasitol. 1979 Jun;65(3):414–417. [PubMed] [Google Scholar]
  10. Romero P. J., Tam J. P., Schlesinger D., Clavijo P., Gibson H., Barr P. J., Nussenzweig R. S., Nussenzweig V., Zavala F. Multiple T helper cell epitopes of the circumsporozoite protein of Plasmodium berghei. Eur J Immunol. 1988 Dec;18(12):1951–1957. doi: 10.1002/eji.1830181213. [DOI] [PubMed] [Google Scholar]
  11. Vanderberg J., Nussenzweig R., Most H. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites. Mil Med. 1969 Sep;134(10):1183–1190. [PubMed] [Google Scholar]
  12. Wortman A., Rogers P., Charoenvit Y., McDermott A., Leef M., Sedegah M., Beaudoin R. L. Cloning of Plasmodium yoelii genes expressing three different sporozoite-specific antigens. Microb Pathog. 1989 Mar;6(3):227–231. doi: 10.1016/0882-4010(89)90072-7. [DOI] [PubMed] [Google Scholar]
  13. Zavala F., Tam J. P., Barr P. J., Romero P. J., Ley V., Nussenzweig R. S., Nussenzweig V. Synthetic peptide vaccine confers protection against murine malaria. J Exp Med. 1987 Nov 1;166(5):1591–1596. doi: 10.1084/jem.166.5.1591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Zavala F., Tam J. P., Hollingdale M. R., Cochrane A. H., Quakyi I., Nussenzweig R. S., Nussenzweig V. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science. 1985 Jun 21;228(4706):1436–1440. doi: 10.1126/science.2409595. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES